{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"1"}],"units":"Participants"}],"description":"Venous blood samples were drawn for analysis of ADAs to GEN3014.","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"OG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG007","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG008","title":"R/R DLBCL Expansion Part A: GEN3014"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity Analysis Set=all enrolled participants who received at least 1 dose of trial drug, had a baseline and at least 1 evaluable on-treatment ADA sample.","reportingStatus":"POSTED","timeFrame":"Dose Escalation: Baseline up to a max of approx. 34.5 months, Expansion Part A: Baseline up to a max of approx. 16.6 months","title":"Dose Escalation and Expansion Part A: Number of Participants With Anti-Drug Antibodies (ADAs) to GEN3014","type":"SECONDARY","unitOfMeasure":"Participants"}